Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/34774
Tüm üstveri kaydı
Dublin Core Alanı | Değer | Dil |
---|---|---|
dc.contributor.author | Yener, Neslihan Parmak | - |
dc.contributor.author | Kılınçel, Oğuzhan | - |
dc.contributor.author | Gündüz, Cem | - |
dc.date.accessioned | 2023-11-03T09:59:12Z | - |
dc.date.available | 2023-11-03T09:59:12Z | - |
dc.date.issued | 2018-05 | - |
dc.identifier.citation | Gündüz, G. U. vd. (2018). ''How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients?''. Journal of Ocular Pharmacology and Therapeutics, 34(4), 354-359. | en_US |
dc.identifier.issn | 1080-7683 | - |
dc.identifier.issn | 1557-7732 | - |
dc.identifier.uri | https://doi.org/10.1089/jop.2017.0133 | - |
dc.identifier.uri | https://www.liebertpub.com/doi/10.1089/jop.2017.0133 | - |
dc.identifier.uri | http://hdl.handle.net/11452/34774 | - |
dc.description.abstract | Purpose: To evaluate anterior segment parameters and intraocular pressure (IOP) modifications in patients using serotonin noradrenaline reuptake inhibitors (SNRIs) due to major depressive disorder. Methods: This cross-sectional study included 170 eyes of 85 subjects. All subjects were divided into three groups: group 1 included 44 healthy control subjects, group 2 included 22 patients receiving antidepressants for 1 week to 6 months, and group 3 included 19 patients receiving antidepressants for >6 months. All subjects underwent a detailed ophthalmologic examination, including gonioscopy. Anterior segments of all subjects were evaluated with the Scheimpflug system and pupil diameter (PD), central corneal thickness, anterior chamber depth (ACD), anterior chamber volume, and anterior chamber angle (ACA) measurements were enrolled. Results: The median IOP was significantly lower in patients using antidepressants [16.0 (11.0-21.0) mmHg] than the control group [17.5 (12.0-21.0) mmHg] (P=0.041). The PD was significantly larger in patients using antidepressants [3.56 (2.29-5.60) mm] than the control group [2.95 (2.00-4.40) mm] (P=0.000). In the study group, PD was also significantly larger in patients using SNRIs for 6 months [3.67 (2.38-5.08) mm] than <6 months [3.31 (2.29-5.60) mm] (P=0.000). The median ACD was significantly lower in patients using antidepressants for 6 months [3.21 (2.52-4.06) mm] than the control group [3.44 (2.63-4.29) mm] (P=0.000). ACAs were measured between 25 degrees and 55 degrees by Scheimpflug imaging. Conclusions: Treatment of SNRIs causes mydriasis and decrease in width of ACD. These changes may not increase IOP as long as the patient has an open angle. SNRIs lead to decrease in IOP particularly in long-term usage. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Mary Ann Liebert | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Ophthalmology | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | Anterior segment parameters | en_US |
dc.subject | Intraocular pressure | en_US |
dc.subject | Serotonin noradrenaline reuptake inhibitors | en_US |
dc.subject | Angle-closure glaucoma | en_US |
dc.subject | Venlafaxine | en_US |
dc.subject | Mechanisms | en_US |
dc.subject | Expression | en_US |
dc.subject | Potent | en_US |
dc.subject | Agents | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Antidepressive agents | en_US |
dc.subject.mesh | Cross-sectional studies | en_US |
dc.subject.mesh | Depressive disorder, major | en_US |
dc.subject.mesh | Duloxetine hydrochloride | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Intraocular pressure | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Serotonin and noradrenaline reuptake inhibitors | en_US |
dc.subject.mesh | Venlafaxine hydrochloride | en_US |
dc.subject.mesh | Young adult | en_US |
dc.title | How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients? | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000425183200001 | tr_TR |
dc.identifier.scopus | 2-s2.0-85046906129 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Göz Hastalıkları Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 354 | tr_TR |
dc.identifier.endpage | 359 | tr_TR |
dc.identifier.volume | 34 | tr_TR |
dc.identifier.issue | 4 | tr_TR |
dc.relation.journal | Journal of Ocular Pharmacology and Therapeutics | en_US |
dc.contributor.buuauthor | Gündüz, Gamze Uçan | - |
dc.contributor.researcherid | AAH-6661-2021 | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.identifier.pubmed | 29446702 | tr_TR |
dc.subject.wos | Ophthalmology | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q3 | en_US |
dc.contributor.scopusid | 57204236887 | tr_TR |
dc.subject.scopus | Bilateral; Angle Closure Glaucoma; Topiramate | en_US |
dc.subject.emtree | Duloxetine | en_US |
dc.subject.emtree | Serotonin noradrenalin reuptake inhibitor | en_US |
dc.subject.emtree | Venlafaxine | en_US |
dc.subject.emtree | Antidepressant agent | en_US |
dc.subject.emtree | Duloxetine | en_US |
dc.subject.emtree | Serotonin noradrenalin reuptake inhibitor | en_US |
dc.subject.emtree | Venlafaxine | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Anterior chamber volume | en_US |
dc.subject.emtree | Anterior eye chamber angle | en_US |
dc.subject.emtree | Anterior eye chamber depth | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Central corneal thickness | en_US |
dc.subject.emtree | Clinical evaluation | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Cross-sectional study | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gonioscopy | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Intraocular pressure | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Major depression | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Ophthalmology | en_US |
dc.subject.emtree | Psychopharmacotherapy | en_US |
dc.subject.emtree | Pupil | en_US |
dc.subject.emtree | Visual system parameters | en_US |
dc.subject.emtree | Adolescent | en_US |
dc.subject.emtree | Drug effects | en_US |
dc.subject.emtree | Intraocular pressure | en_US |
dc.subject.emtree | Major depression | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Young adult | en_US |
Koleksiyonlarda Görünür: | Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.